5:46 PM
Login form
Entries archive

My site

Main » 2023 » January » 07

Agreement reinforces Organon’s continued focus on pursuing new solutions in high-need areas of women’s health

(BUSINESS WIRE) -- Organon (NYSE: OGN), a global women’s healthcare company, today announced a strategic investment in Claria Medical, Inc. a privately-held company developing an investigational medical device being studied for use during minimally invasive laparoscopic hysterectomy. The agreement also grants Organon the option to acquire Claria Medical.

“Hysterectomy is one of the most commonly performed surgeries for women,[1] which is why it is critical to invest in new technology with the goal of providing safer, simpler and faster procedures,” said Kevin Ali, Organon’s CEO. “Collaborations such as our agreement with Claria Medical are integral to our business development approach. We search across the entire horizon for potential solutions—be they medicines, devices, or other technologies— that can im ... Read more »

Views: 62 | Added by: africa-live | Date: 01.07.2023 | Comments (0)

(BUSINESS WIRE) -- The Hisense Group is pleased to announce that it has joined the Connectivity Standards Alliance and will bring support for the Matter protocol to its products starting in 2023, helping to simplify and elevate consumers’ experience through seamless integration and interoperability of all their smart home devices. Hisense Group's portfolio includes consumer electronics and home appliance brands such as Hisense, Toshiba, Gorenje, ASKO, and ATAG, as well as smart device platforms such as ConnectLife and VIDAA.

These brands will grow to include Matter compatible electronics and appliances going forward.

Matter is a new, open smart home protocol supported by many companies, both major leaders and smaller players, creating an unmatched force in the future of smart homes. Matter strives to ensure seamless connectivity of all devices, from a lightbulb to smart TVs to major domestic appliances, without worrying about compatibility.

“A ... Read more »

Views: 77 | Added by: africa-live | Date: 01.07.2023 | Comments (0)

In 2018, 1NCE disrupted the IoT connectivity industry with its Lifetime Flat service; now 1NCE takes aim at the IoT software industry
Available in 153 countries, the service now includes complimentary tools to transform data into actionable insights with minimal effort
1NCE OS’s powerful IoT software accelerates customer time-to-market by months and makes development of connected products easier than ever
(BUSINESS WIRE) -- 1NCE, a global IoT connectivity and software company, today announced the creation of its software business unit in conjunction with the Consumer Electronics Show launch of 1NCE OS – IoT software offering powerful developer tools and device control to make IoT even more accessible.

The software tools are an integral part of 1NCE’s Lifetime Flat service and are available complimentary to 1NCE customers.

1NCE OS is a foundational element of the company’s ambitious goal: to cement 1NCE’s standing ... Read more »

Views: 72 | Added by: africa-live | Date: 01.07.2023 | Comments (0)

Takeda Announces Favorable Phase 3 Safety and Efficacy Results of TAK-755 as Compared to Standard of Care in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

OSAKA, Japan & CAMBRIDGE, Mass. - Thursday, 05. January 2023

  • Results are From First and Only Phase 3 Trial in cTTP, an Ultra-Rare Disease with Limited Treatment Options
  • cTTP is Caused by a Deficiency in ADAMTS13 Protease; 1 TAK-755 Is Designed to Replace Missing or Deficient ADAMTS13 Enzyme2
  • Takeda Plans to Seek Marketing Authorization for TAK-755 as the First ADAMTS13 Replacement Therapy for the Treatment of cTTP

(BUSINESS WIRE) --Takeda (TSE:4502/NYSE:TAK) today announced that the totality of evidence from a pre-planned interim analysis of a pivotal Phase 3 study supports the efficacy and safety of TAK-755 as enzyme replacement therapy for congenital thrombotic thrombocytopenic purpura (cTTP). ... Read more »

Views: 74 | Added by: africa-live | Date: 01.07.2023 | Comments (0)